Immunohistochemical markers expression in hysteroscopy and hysterectomy specimens from endometrial cancer patients: comparison

Authors: R. Pilka 1;  I. Marková 2;  M. Dušková 3;  J. Zapletalová 4;  M. Tozzi 1;  M. Kudela 1
Authors‘ workplace: Porodnicko-gynekologická klinika, FN a LF UP, Olomouc, přednosta doc. MUDr. R. Pilka, Ph. D. 1;  Ústav genetiky a fetální medicíny, FN a LF UP, Olomouc, přednosta prof. MUDr. J. Šantavý, CSc. 2;  Ústav patologické anatomie, FN a LF UP, Olomouc, přednosta doc. MUDr. M. Tichý, CSc. 3;  Ústav lékařské biofyziky, pracoviště biometrie, LF UP, Olomouc, přednostka doc. RNDr. H. Kolářová, CSc. 4
Published in: Ceska Gynekol 2010; 75(3): 165-170


To assess the immunohistochemical expression of p53, bcl-2, c-erbB-2, Ki-67, estrogen (ER) and progesterone receptors (PR), MMP-7, MMP-26 in samplex from diagnostic hysteroscopy and therapeutic hysterectomy in endometrial cancer patients.

Experimental prospective study.

Department of Obstetrics and Gynecology, Institute of Human Genetics, Department of Pathology, Palacky University Medical School and University Hospital, Olomouc.

We studied 43 cases of primary untreated endometrial carcinoma in which the grade and immunomarkers assessed by histoscore were investigated in specimens obtained at hysteroscopy and hysterectomy.

Based on hysterosopy, 31 (72.1%) patients were classified as G1, G2 7 (16.3%) and G3 5 (11.6%) respective. In grade 1 the concordance rate was 77.4% of cases, in grade 2 it was in 14.3% of cases and in grade 3 it was in 80.0% of cases.

In hysterosocpy samples the p53 expression was found in 23 (53.5%), bcl-2 in 37 (86.0%), c-erbB-2 in 20 (46.5%), Ki-67 in 29 (67.4%), ER in 37 (86.0%), PR in 36 (83.7%), MMP-7 in 25 (58.1%) and MMP-26 in 23 (53.5%) cases.

Expression in hysterectomy specimens was p53 positive in 13 (30.2%), bcl-2 positive in 33 (76.7%), c‑erbB-2 positive in 24 (55.8%), Ki-67 positive in 25 (58.1%), ER positive in 36 (83.7%), PR positive in 40 (93.0%), MMP-7 positive in 27 (62.8%) and MMP-26 positive in 23 (53.5%) of total 43 cases.

We found high concordance in expression of p53, bcl-2, PR and MMP-7 in hysteroscopy and hysterectomy samples which could be of importance for therapeutic algorithm in endometrial cancer patients.

Key words:
endometrial cancer, immunohistochemistry, prognostic factors, hysteroscopy.


1. American Cancer Society, in Cancer facts and figures, 1995. Atlanta: American Cancer Society, 1995.

2. Amant, F., Moerman, P., Neven, P., et al. Endometrial cancer. Lancet, 2005, 366, p. 491–505.

3. Archer, DF., McIntyre-Seltman, K., Wilborn, WW. Jr., et al. Endometrial morphology in asymptomatic postmenopausal women. Am J Obstet Gynecol, 1991, 165. p. 317-20; discussion 320-322.

4. Barakat, R. Principles and practice of gynecologic oncology, 2nd ed. Philadelphia: Lippincott-Raven, 1997.

5. Cowles, TA., Magrina, JF., Masterson, BJ., et al. Comparison of clinical and surgical-staging in patients with endometrial carcinoma. Obstet Gynecol, 1985, 66, p. 413-416.

6. Creasman, WT., Morrow, CP., Bundy, BN., et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer, 1987, 60. p. 2035-2041.

7. Dzvincuk, P., Pilka, R., Kudela, M., et al. [Histological grade in management of carcinoma of endometrium]. Ces Gynek, 2005, 70, p. 201-205.

8. Engelsen, IB., Stefansson, I., Akslen, LA., et al. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. Am J Obstet Gynecol, 2006, 195, p. 979-986.

9. Erdem, O., Erdem, M., Dursun, A., et al. Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables. Int J Gynecol Pathol, 2003, 22, p. 254-260.

10. Ferrandina, G., Ranelletti, FO., Gallotta, V., et al. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer. Gynecol Oncol, 2005, 98, p. 383-389.

11. Fitzgibbons, PL., Page, DL., Weaver, D., et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med, 2000, 124, p. 966-978.

12. Frumovitz, M., Singh, DK., Meyer, L., et al. Predictors of final histology in patients with endometrial cancer. Gynecol Oncol, 2004, 95, p. 463-468.

13. Geisler, JP., Wiemann, MC., Zhou, Z., et al. p53 as a prognostic indicator in endometrial cancer. Gynecol Oncol, 1996, 61, p. 245-248.

14. Halperin, R., Zehavi, S., Habler, L., et al. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol, 2001, 22, p. 122-126.

15. Jalava, P., Kuopio, T., Huovinen, R., et al. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints. Anticancer Res, 2005, 25, p. 2535-2542.

16. Kadar, N., Malfetano, JH., Homesley, HD. Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients. Gynecol Oncol, 1993, 50, p. 281-286.

17. Kirby, TO., Leath, CA. 3rd, Kilgore, LC. Surgical staging in endometrial cancer, Oncology (Williston Park). 2006, 20, p. 45-50; discussion p. 50, 53-54, 63.

18. Kudela, M., Pilka, R. Is there a real risk in patients with endometrial carcinoma undergoing diagnostic hysteroscopy (HSC)? Eur J Gynaecol Oncol, 2001, 22, p. 342-344.

19. Lampe, B., Kurzl, R., Hantschmann, P. Reliability of tumor typing of endometrial carcinoma in prehysterectomy curettage. Int J Gynecol Pathol, 1995, 14, p. 2-6.

20. Larson, DM., Johnson, KK., Broste, SK., et al. Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer, Obstet Gynecol, 1995, 86, p. 38-42.

21. Lax, SF., Pizer, ES., Ronnett, BM., et al. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol, 1998, 29, p. 551-558.

22. Mangioni, C., De Palo, G., Marubini, E., et al. Surgical pathologic staging in apparent stage I endometrial carcinoma. Int J Gynecol Cancer, 1993, 3, p. 373-384.

23. Mariani, A., Sebo, TJ., Katzmann, JA., et al. Pretreatment assessment of prognostic indicators in endometrial cancer. Am J Obstet Gynecol, 2000, 182, p. 1535-1544.

24. Mariani, A., Sebo, TJ., Katzmann, JA., et al. Endometrial cancer: can nodal status be predicted with curettage? Gynecol Oncol, 2005, 96, p. 594-600.

25. Mariani, A., Sebo, TJ., Webb, MJ., et al. Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detect Prev, 2003, 27, p. 434-441.

26. Mitchard, J., Hirschowitz, L. Concordance of FIGO grade of endometrial adenocarcinomas in biopsy and hysterectomy specimens. Histopathology, 2003, 42, p. 372-378.

27. Morris, PC., Anderson, JR., Anderson, B., et al. Steroid hormone receptor content and lymph node status in endometrial cancer. Gynecol Oncol, 1995, 56, p. 406-411.

28. Oakley, G., Nahhas, WA. Endometrial adenocarcinoma: therapeutic impact of preoperative histopathologic examination of endometrial tissue. Eur J Gynaecol Oncol, 1989, 10, p. 255-260.

29. Ogawa, Y., Moriya, T., Kato, Y., et al. Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer, 2004, 11, p. 267-275.

30. Ohkouchi, T., Sakuragi, N., Watari, H., et al. Prognostic significance of Bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma. Am J Obstet Gynecol, 2002, 187, p. 353-359.

31. Onnis, A., Marchetti, M., Maggino, T., et al. Clinical experience in gynecological cancer management. Endometrial cancer: report from the gynecological institutes of Padua university (1963-1989). Eur J Gynaecol Oncol, 1990, 11, p. 1-11.

32. Oreskovic, S., Babic, D., Kalafatic, D., et al. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol Oncol, 2004, 93, p. 34-40.

33. Parkin, DM. Cancers of the breast, endometrium and ovary: geographic correlations. Eur J Cancer Clin Oncol, 1989, 25, p. 1917-1925.

34. Petersen, RW., Quinlivan, JA., Casper, GR., et al. Endometrial adenocarcinoma – presenting pathology is a poor guide to surgical management. Aust N Z J Obstet Gynaecol, 2000, 40, p. 191-194.

35. Pilka, R., Norata, GD., Domanski, H., et al. Matrix metalloproteinase-26 (matrilysin-2) expression is high in endometrial hyperplasia and decreases with loss of histological differentiation in endometrial cancer. Gynecol Oncol, 2004, 94, p. 661-670.

36. Pisani, AL., Barbuto, DA., Chen, D., et al. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol, 1995, 85, p. 729-734.

37. Piver, MS., Lele, SB., Barlow, JJ., et al. Paraaortic lymph node evaluation in stage I endometrial carcinoma. Obstet Gynecol, 1982, 59, p. 97-100.

38. Sakuragi, N., Ohkouchi, T., Hareyama, H., et al. Bcl-2 expression and prognosis of patients with endometrial carcinoma. Int J Cancer, 1998, 79, p. 153-158.

39. Salvesen, HB., Iversen, OE., Akslen, LA. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res, 1998, 4, p. 2779-2785.

40. Salvesen, HB., Iversen, OE., Akslen, LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol, 1999, 17, p. 1382-1390.

41. Sant Cassia, LJ., Weppelmann, B., Shingleton, H., et al. Management of early endometrial carcinoma. Gynecol Oncol, 1989, 35, p. 362-366.

42. Silverman, MB., Roche, PC., Kho, RM., et al. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma. Gynecol Oncol, 2000, 77, p. 1-7.

43. Trimble, EL., Kosary, C. , Park, RC. Lymph node sampling and survival in endometrial cancer. Gynecol Oncol, 1998, 71, p. 340-343.

44. Ueno, H., Yamashita, K., Azumano, I., et al. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int J Cancer, 1999, 84, p. 470-477.

45. Wang, X., Huang, Z., Di, W., et al. Comparison of D&C and hysterectomy pathologic findings in endometrial cancer patients. Arch Gynecol Obstet, 2005, 272, p. 136-141.

46. Wolfson, AH., Sightler, SE., Markoe, AM., et al. The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol, 1992, 45, p. 142-146.

47. Yamauchi, N., Sakamoto, A., Uozaki, H., et al. Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity. Int J Gynecol Pathol, 1996, 15, p. 202-208.

Paediatric gynaecology Gynaecology and obstetrics Reproduction medicine
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account